Black Diamond Therapeutics, Inc. (BDTX) stock
BDTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.47−0.05 (-3.29%)
Close on Nov 13, 2026Market cap $84.46MP/E –Yield –
Black Diamond Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Black Diamond Therapeutics's total assets was $115.56M at Sep 30, 2026. For fiscal 2025 it was $143.01M, up 16.6% from the year before. The highest annual figure on record is $329.67M in fiscal 2020.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $143.01M | +16.6% |
| FY2024 | Dec 31, 2024 | $122.64M | -22.7% |
| FY2023 | Dec 31, 2023 | $158.57M | +1.5% |
| FY2022 | Dec 31, 2022 | $156.26M | -36.9% |
| FY2021 | Dec 31, 2021 | $247.68M | -24.9% |
| FY2020 | Dec 31, 2020 | $329.67M | +108.3% |
| FY2019 | Dec 31, 2019 | $158.30M | +205.4% |
| FY2018 | Dec 31, 2018 | $51.83M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $115.56M | -26.7% |
| Q2 FY2026 | Jun 30, 2026 | $125.03M | -24.9% |
| Q1 FY2026 | Mar 31, 2026 | $132.92M | -24.6% |
| Q4 FY2025 | Dec 31, 2025 | $143.01M | +16.6% |
| Q3 FY2025 | Sep 30, 2025 | $157.73M | +14.4% |
| Q2 FY2025 | Jun 30, 2025 | $166.39M | +10.9% |
| Q1 FY2025 | Mar 31, 2025 | $176.25M | +23.7% |
| Q4 FY2024 | Dec 31, 2024 | $122.64M | -22.7% |
| Q3 FY2024 | Sep 30, 2024 | $137.90M | -20.0% |
| Q2 FY2024 | Jun 30, 2024 | $149.99M | +25.1% |
| Q1 FY2024 | Mar 31, 2024 | $142.52M | +5.1% |
| Q4 FY2023 | Dec 31, 2023 | $158.57M | +1.5% |
| Q3 FY2023 | Sep 30, 2023 | $172.38M | -4.5% |
| Q2 FY2023 | Jun 30, 2023 | $119.88M | -39.7% |
| Q1 FY2023 | Mar 31, 2023 | $135.58M | -38.2% |
| Q4 FY2022 | Dec 31, 2022 | $156.26M | -36.9% |
| Q3 FY2022 | Sep 30, 2022 | $180.42M | -34.2% |
| Q2 FY2022 | Jun 30, 2022 | $198.83M | -30.9% |
| Q1 FY2022 | Mar 31, 2022 | $219.48M | -29.9% |
| Q4 FY2021 | Dec 31, 2021 | $247.68M | -24.9% |
| Q3 FY2021 | Sep 30, 2021 | $274.13M | -20.9% |
| Q2 FY2021 | Jun 30, 2021 | $287.88M | -17.6% |
| Q1 FY2021 | Mar 31, 2021 | $313.26M | -13.7% |
| Q4 FY2020 | Dec 31, 2020 | $329.67M | +108.3% |
| Q3 FY2020 | Sep 30, 2020 | $346.44M | +568.5% |
| Q2 FY2020 | Jun 30, 2020 | $349.45M | – |
| Q1 FY2020 | Mar 31, 2020 | $362.80M | – |
| Q4 FY2019 | Dec 31, 2019 | $158.30M | – |
| Q4 FY2018 | Dec 31, 2018 | $51.83M | – |
See a number that looks wrong?